Development of biomarker to predict postpoerative delirium and postoperative cognitive decline in cancer patients

Development of biomarker to predict postpoerative delirium and postoperative cognitive decline in cancer patients - Delirium Mechanism (DM) study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038894

Enrollment

320

Registered

2019-12-16

Start date

2018-04-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium Postoperative cognitive decline

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who plan to undertake highly invasive cancer resection, surgery under general anesthesia generally considered to take over 6 hours or surgery considered as highly invasive based on expert opinion from a surgeon among those come to an outpatient clinic or are admitted to the national cancer center hospital (regardless of the actual surgical time as long as surgical procedure is not substantially changed).

Exclusion criteria

Exclusion criteria: 1. Delirium diagnosis at informed consent 2. Judgement of inappropriateness by the manager or member of research project

Design outcomes

Primary

Measure	Time frame
Immunological factor associated with the onset of postoperative delirium and postoperative cognitive decline.	—

Secondary

Measure	Time frame
Metabolomics, epigenome, gene expression, clinical factor, physical remark, electroencephalography associated with the onset of postoperative delirium and postoperative cognitive decline.	—

Countries

Japan

Contacts

Public ContactRyoichi Sadahiro

National Cancer Center Japan National Cancer Center Hospital, Department of Psycho-oncology

rsadahir@ncc.go.jp0335422511

Outcome results